EUVIMEDEUVIMED entdecken
Crossref

Delineation of clinical course, outcomes, and prognostic factors in patients with T‐cell prolymphocytic leukemia

Ashley Rose, Ling Zhang, Akriti G Jain iD, Abida Poovathukaran Babu iD, Lubomir Sokol, Hayder Saeed, Qianxing Mo, Wenyi Fan, Xiaohui Zhang iD

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Ashley Rose und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Leukemia, Prolymphocytic, T-Cell, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T‐cell prolymphocytic leukemia (T‐PLL) is a rare, post‐thymic T‐cell neoplasm with a diverse clinical course. T‐PLL is typically associated with a poor prognosis; however, a subset of patients have inactive disease on initial presentation. There is a lack of accurate delineation of the disease based on initial clinical presentation and pathological assessment, hindering clinical decision‐making. To characterize and delineate disease subtypes based on initial clinical presentation and pathologic assessment, we retrospectively reviewed 81 patients with T‐PLL treated at our institution. We compared patients with T‐PLL who initially presented with a relatively indolent or stable disease course to those with an aggressive disease course. Clinicopathologic characteristics, overall survival (OS), and prognostic factors were analyzed. Patients with inactive disease had a significantly longer OS than patients with active disease. At diagnosis, presence of B symptoms, low hemoglobin, low platelet count, lymphocyte doubling time of fewer than 3 months, and abnormal cytogenetics were associated with shorter OS. Cell morphology, immunophenotype, absolute lymphocyte count, lactate dehydrogenase levels, involvement of liver, spleen, skin or central nervous system, presence of TCL1 rearrangement or inv (14)/t(14;14), presence of chromosome 8 abnormalities, and presence of deletion of 11q were not associated with significant OS difference among the patients. Receiving alemtuzumab as first‐line treatment and consolidation with allogeneic hematopoietic stem cell transplant were associated with better outcomes. T‐PLL inactive and active disease subtypes can exhibit overlapping yet different clinical and pathological features. We describe several prognostic factors at diagnosis that can be used for risk stratification and aid in guiding treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Prolymphocytic, T-CellHematopoietic Stem Cell TransplantationHumansPrognosisRetrospective StudiesChromosome AberrationsDisease Progression

Autor:innen und Institutionen

  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Department of Internal Medicine, University of South Florida College of Medicine, Tampa, Florida, USA.
  • Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

ORCID-Profile: Akriti G Jain, Abida Poovathukaran Babu, Xiaohui Zhang

Förderung

  • NCI NIH HHS

Zitieren

APA

Rose, A., Zhang, L., Jain, A. G., Poovathukaran Babu, A., Sokol, L., Saeed, H., Mo, Q., Fan, W., & Zhang, X. (2023). Delineation of clinical course, outcomes, and prognostic factors in patients with T‐cell prolymphocytic leukemia. American Journal of Hematology. https://doi.org/10.1002/ajh.26918

Vancouver

Rose A, Zhang L, Jain AG, Poovathukaran Babu A, Sokol L, Saeed H, et al. Delineation of clinical course, outcomes, and prognostic factors in patients with T‐cell prolymphocytic leukemia. American Journal of Hematology. 2023. doi:10.1002/ajh.26918

BibTeX
@article{Rose2023,
  author = {Rose, Ashley and Zhang, Ling and Jain, Akriti G and Poovathukaran Babu, Abida and Sokol, Lubomir and Saeed, Hayder and Mo, Qianxing and Fan, Wenyi and Zhang, Xiaohui},
  title = {Delineation of clinical course, outcomes, and prognostic factors in patients with T‐cell prolymphocytic leukemia},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26918}
}
Kostenlos starten →